AD-120A: Administered before the breakfast during 7 days, Oral, Tablet
AD-120: Administered before the breakfast during 7 days, Oral, Tablet
Study summary
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.
Eligibility
Sex
ALL
Min age
19 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Body weight equal to or greater than 50.0kg and equal to or less than 90.0kg and Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit
* The Age equal to or greater than 19 and equal to or less than 50 in healthy volunteers at the time of screening visit
* Negative result from Serum Helicobacter pylori antibody at the time of screening visit
Exclusion Criteria:
* Patients with trouble performing pH monitor catheter
Primary outcome measure(s)
Area under the plasma concentration-time curve over a dosing interval at steady state (AUCτ,ss) — AUCτ,ss: pre-dose to 24 hours of 1st administration versus pre-dose to 24 hours of repeated administration (7days) AUCτ,ss after 7days repeated administration of Omeprazole
The time of peak concentration after single dose — Tmax: from pre-dose to 24 hours of 1st administration Tmax after 1days administration of Omeprazole
Percent decrease from baseline in integrated gastric acidity measured by 24h pH monitoring — 24 hours before 1st administration to 24 hours after repeated administration (7days) Percent decrease from baseline in integrated gastric acidity measured by 24h pH monitoring for 24-hour interval after 7th dose
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.